Goodwin Advises Pharmakon Advisors on Intellectual Property Aspects for $500 Million Debt Facility With Mineralys Therapeutics
The Intellectual Property team advised Pharmakon Advisors, LP, on entering into a $500 million committed debt facility with Mineralys Therapeutics. The term loan will be available to Mineralys in four tranches, with the first tranche of $100 million to be funded upon closing. Mineralys is developing the investigational drug lorundrostat, a small molecule aldosterone synthase inhibitor in clinical trials for treating hypertension.
Pharmakon Advisors, LP is a leading investor in non-dilutive debt for the life sciences industry and is the investment manager of the BioPharma Credit funds. Established in 2009, funds managed by Pharmakon Advisors, LP, have committed up to $12 billion across 76 investments.
The Goodwin team was led by Carl Morales, Kevin Grumberg, Xixi Sun, Gina Kim, Cathy Amaya, Mariah Meyer, and Tyler Garaffa.
For more information on the deal, please read the press release.